Navigation Links
Mindray Announces Third Quarter 2009 Financial Results
Date:11/9/2009

diluted 0.24 0.38 0.68 0.90 Shares used in computation of: Basic earnings per share 107,538,933 108,845,481 107,256,059 108,337,457 Diluted earnings per share 114,573,283 113,374,202 114,130,393 112,671,743 Non-GAAP operating income 37,516 40,028 108,307 118,617 Non-GAAP operating margin 25.6% 26.5% 28.5% 26.6% Amortization of acquired intangible assets (4,789) (2,135) (15,279) (6,484) Realignment costs - post acquisition and termination payments -- (1,030) -- (1,261) Share-based compensation (2,577) (2,636) (7,162) (8,249) GAAP operating income 30,150 34,227 85,866 102,623 GAAP operating margin 20.6% 22.6% 22.6% 23.0% Non-GAAP gross profit 83,586 87,153 213,675 256,806 Non-GAAP gross margin 57.0% 57.7% 56.3% 57.7% Amortization of acquired intangible assets (4,066) (1,508) (7,536) (4,616) Share-based compensation (113) (124) (334) (373) GAAP gross profit 79,407 85,521 205,805 251,817 GAAP gross margin 54.2% 56.6% 54.2% 56.5% Exhibit 4 MINDRAY MEDICAL INTERNATIONAL LIMITED RECONCILIATION OF GAAP NET INCOME TO EARNINGS BEFORE INTEREST, TAX, DEPRECIATION AND AMORTIZATION(Dollars in thousands) Three months ended Nine months ended September 30, September 30, 2008 2009 200
'/>"/>
SOURCE Mindray Medical International Limited
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine news :

1. Mindray Selects Actel Low-Power Flash FPGAs for Demanding Medical Equipment Applications
2. Mindray to Report Third Quarter 2007 Financial Results on November 1, 2007
3. Mindray to Attend 2007 RSNA Conference in Chicago
4. Mindray to Attend 2008 CLSA Asia Investors Forum
5. Mindray to Exhibit at 2008 European Congress of Radiology Annual Meeting
6. Mindray to Report Fourth Quarter and Fiscal Year 2007 Financial Results on March 5, 2008
7. Mindray Medical International Announces Full Year and Fourth Quarter 2007 Results
8. Mindray to Attend the 11th Credit Suisse Asian Investment Conference
9. Mindrays Laptop-size M5 and BS-200 Receive FDA Clearance
10. Mindray to Attend the JPMorgan 4th Annual China Conference
11. Mindray to Exhibit at 2008 China International Medical Equipment Fair

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...ERSPRING,Md.,Nov.25/PRNewswire-USNewswire/--Anarti...rDrugEvaluationandResearch,titled"ADifficultBalanc...eNov.26,2009issueofTheNewEnglandJournalofMedicine....20090824/FDALOGO ) ,, Inthearticle,Woodcockdisc...medicationforthosewhoneeditandmanagingtheriskspose...
(Date:11/25/2009)...s have found evidence of a statistically significa...patients whose estrogen receptor (ER)-positive tum...; at serine-118 (ER-alpha S118-P), according to a ...n the Journal of the National Cancer Institute . ...istant to tamoxifen. Preclinical studies have show...
(Date:11/25/2009)... Evaluation and treatment clinics to ...Woodstock (Vocus) November 25, 2009 -- Centegra He...ines and H1N1 vaccine shots at four Centegra Prima...ipment of vaccine has arrived. The clinics are at ...McHenry and will be open as follows: ,   ...
(Date:11/25/2009)...NGTON,Va.,Nov.25/PRNewswire-USNewswire/--TheAmeric...thCareFraudActof2009,"S.2128,whichisdesignedtosubs...tfraudinMedicare.ThebillwasintroducedbySen.GeorgeL...lprovisionstheAmericanAssociationforHomecareoutlin...ationproposedtoCongressinFebruary.Thoseprovisionsi...
(Date:11/25/2009)...ks placed under the skin kill tumor cells, study f...ews) -- A cancer vaccine delivered in a fingernail...a new study reports. , The method uses polymer ...d with tumor-specific antigens and implanted under... tumors. The Harvard University scientists who dev...
Breaking Medicine News(10 mins):Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 2Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 3Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 4Health News:American Association for Homecare Endorses New U.S. Senate Bill, the 'Prevent Health Care Fraud Act of 2009' 2
...tial financial income and the c...ime is a precious commodity, and so,people are inc... their,time, especially when it comes to financial...rgest online and catalog companies catering,exclus...
...ior Management Team, NASHVILLE, Tenn., May 20 Em...nue cycle management and clinical communication,so...as been named Senior,Vice President of Corporate S...ntly, Ms. Paramore was a,Partner with Commonwealth...
...fits of,lipid-modifying drugs, current management ...n a new supplement to The Journal of Family,Practi... in aggressive,lipid lowering" reviews the evidenc... patients., "High-dose statin therapy: Benefits a...
...in key organs , , TUESDAY, May 20 (HealthD...lso protect against adenovirus, which causes upper...uses that causes the common cold. , Currently, the...hing that needs to be done before new drugs can be...
...oomers,have challenged many industries to replace ...the multi-generational workforce is challenging,co...s to engage employees,and to define a new type of ...long,term strategies through dynamic case study pr...
...s with latent tuberculosis (TB), who are infected ...t it in less than half the time and at a lower cos...o researchers who conducted a multi-center, random... We found that using a therapy of four months of R...
Other Medicine News:Health News:Lucrative Sales Opportunities Abound With Melaleuca, The Wellness Company(R) 2Health News:Emdeon Business Services Names Miriam Paramore Senior Vice President of Corporate Strategy 2Health News:Reductions in CV Morbidity and Mortality are Achievable! 2Health News:Smallpox Drug May Protect Against Common Cold 2Health News:Fortune 500s to Convene in Florida, Sharing Insights & Best Practices for Developing Tomorrow's Leaders 2Health News:Rifampin: Latent TB treatment saves time money and lives 2
(Date:11/25/2009)...swire/--AccordingtoMillenniumResearchGroup(MRG),th...nce,thenearly$3billionUSmarketfortraumafixationdev...rsdespitetherecenteconomicslowdown.MRG,s USMarkets...llremainhighlydynamicoverthenextfiveyears,withcomp...derservedsegmentsofthetraumafixationmarket,fueling...
(Date:11/25/2009)...ANNESBURG,November25/PRNewswire/--,iThembaPharmace...oday,thattheyhavesignedacollaborativeagreementtojo...worldclasscomputationalchemistryandleaddiscoveryex...oprovidemedicinaland,syntheticchemistrysupporttopr...etwork.iThembaPharmaceuticalsandPyxisDiscovery,als...
(Date:11/24/2009)...swire-FirstCall/--Endologix,Inc.(Nasdaq: ELGX ),de...ders,announcedtodaythatithasfiledamotiontostay,ord...wsuitbroughtagainstitinOctober2009byCook,Inc.Themo...apolis,Indiana. ,, Endologixhasrequestedthatthe...demarkOffice(USPTO)conductsproceedingstore-examine...
Breaking Medicine Technology:US Trauma Fixation Device Market Not Seeing Signs of Slowdown 2US Trauma Fixation Device Market Not Seeing Signs of Slowdown 3iThemba Pharmaceuticals (Pty) Ltd and Pyxis Discovery B.V. Announce Collaborative Agreement to Offer a Combined Service Offering 2Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement 2BioFit Intensive Plus 26amp 3B 238482 3B Chairs Meet Federal Standard for Continuous Intensive Use 48720 1BioFit Intensive Plus 26amp 3B 238482 3B Chairs Meet Federal Standard for Continuous Intensive Use 48720 2BioFit Intensive Plus 26amp 3B 238482 3B Chairs Meet Federal Standard for Continuous Intensive Use 48720 3Manatees can probably hear which directions boats approach from 8808 1Manatees can probably hear which directions boats approach from 8808 2Hey Governator 21 Dont Terminate Senior Funding 21 48717 1Hey Governator 21 Dont Terminate Senior Funding 21 48717 2Hey Governator 21 Dont Terminate Senior Funding 21 48717 3Hey Governator 21 Dont Terminate Senior Funding 21 48717 4Hey Governator 21 Dont Terminate Senior Funding 21 48717 5
...t, a division of Rigaku,Americas Corporation, anno...-based Lead Discovery (FBLD) Project with CHDI, In..."fragments," to the,active sites of protein drug t...mpounds used in traditional high-throughput screen...hemical space with a smaller screening,library. Ut...
...,multi-disciplinary group of researchers from the ...rsity of Maryland Biotechnology Institute (UMBI),h...Foundation (NSF) grant,to revolutionize the way re... The group, led by William Bentley, Herbert Rabin ...Department of Bioengineering at the,University of ...
Other Medicine Technology:ActiveSight and CHDI Leverage Fragment-Based Lead Discovery for Huntington Disease Therapies 2ActiveSight and CHDI Leverage Fragment-Based Lead Discovery for Huntington Disease Therapies 3U. of Md. Researchers to Develop Devices to Revolutionize Drug Research 2U. of Md. Researchers to Develop Devices to Revolutionize Drug Research 3U. of Md. Researchers to Develop Devices to Revolutionize Drug Research 4U. of Md. Researchers to Develop Devices to Revolutionize Drug Research 5
RIDASCREEN Anti-VZV IgM Assay
...ricella- Zoster Virus (VZV) IgG Enzyme- linked Imm...tion and quantitative determination of IgG antibod... may be used for the determination of immune statu...d to demonstrate seroconversion or a significant r...
...nzyme-Linked Immunosorbent Assay (ELISA) is intend...n of IgG antibody to VZV in human sera. Individua...n of immune status. Paired sera, acute and convale...r a significant rise in antibody level, as an aid ...
RIDASCREEN Anti-Mumps Virus IgM Assay
Medicine Products: